Amedisys Reports Third Quarter Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Piper Jaffray Raises Price Target as Amedisys (AMED) Raises Acquisition Pipeline
November 6, 2015 11:44 AM ESTPiper Jaffray reiterated a Neutral rating on Amedisys (NASDAQ: AMED), and raised the price target to $45.00 (from $42.00), following the company's 3Q report. AMED's acquisition pipeline has increased from 17 potential targets a year ago to over 300. While deal valuations have increased to... More
Amedisys (AMED) Tops Q3 EPS by 1c
November 5, 2015 8:12 AM ESTAmedisys (NASDAQ: AMED) reported Q3 EPS of $0.34, $0.01 better than the analyst estimate of $0.33. Revenue for the quarter came in at $326.44 million versus the consensus estimate of $312.22 million.
Paul B. Kusserow, President and Chief Executive Officer stated, We are encouraged by the companys... More
